“Today is a great day for science and humanity. The first set of results from our phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19,” said Dr. Albert Bourla, the Chairman and CEO of Pfizer, a well- respected company.
On November 09, 2020, Pfizer and BioNTech revealed an important announcement. Their vaccine candidate against COVID-19 achieved the first interim analysis from phrase 3. The vaccine candidate called BNT162b2 is mRNA-based. BNT162b2 is discovered to have an efficacy rate of 90% against COVID-19. This is high among participants identified to have no prior evidence of SARS-CoV-2 infection.
The first interim efficacy analysis was conducted on November 08, 2020. This was done by an external, independent Data Monitoring Committee (DMC) from the phase 3 clinical study. It is a randomized, blind trial among the participants. They get a shot of the vaccine, and they don’t know whether they get the COVID-19 vaccine or not. The people who did were 90% less likely to get COVID-19 than those who got a placebo.
The companies included in this breakthrough recently decided to drop the 32-case interim analysis. They began conducting the first interim analysis with a minimum of 62 cases.
The cases to be evaluated increased to 94 and the DMC performed its first analysis of all the cases. The case was divided into two. First, were the vaccinated participants and those who received the placebo. It indicates a vaccine efficacy rate above 90%, seven days after the second dose. This shows that protection from the virus can be possible to achieve after 28 days from the initiation of the vaccine.
There were over 43 538 participants enrolled in this successful study. The phase three clinical trials started on July 27, 42% of them are global participants, and 30% are from the U.S. Participants were chosen to have diverse racial and ethnic backgrounds.
Fortunately, there were no serious safety concerns that have been observed and identified. Although, safety and additional efficacy data are still in the process of the collection. This is as directed by the amount of safety data asked by the FDA in its guidance for potential Emergency Use Authorization. As of November 8, 2020, 38 955 of the participants received the second dose of the candidate vaccine.
The study is not done yet and is still continuing on enrolling participants. It is expected to continue until the final analysis. Meaning, when a total of 164 confirmed COVID-19 cases have been accumulated over their estimated time frame. The participants in this study will be monitored for two years after the second dose of the vaccine. This is to ensure long-term protection and safety.
The candidate vaccine will also be further evaluated. Why? To see its potential of effectivity amongst those people who have prior exposure to SARS-CoV-2. Also, to provide prevention on severe cases of the virus as new mutations are being reported in several countries.
New secondary endpoints evaluating the efficacy on cases accumulated for 14 days after the second dose will be added. But this should wait until the FDA gives their approval. This is along with the evaluation of the primary efficacy endpoints of the confirmed COVID- 19 cases accumulated from seven days after the second dose of the vaccine.
The addition of the second endpoints will give significant indications as the data across all the COVID-19 vaccine studies could be aligned and allow comparisons between these novel vaccines being created. Pfizer and Biotech are now working on the necessary safety and manufacturing data to be submitted to the FDA and demonstrate the safety and quality of the vaccine.
“We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing- capacity, and economies struggling to reopen.
With today’s news, we are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis.” Dr. Bourla said during the announcement of the major success of the vaccine. They are now targeting to produce 50 million vaccine doses globally by the end of 2020 and up to 1.3 billion doses in 2021.
This major breakthrough proves something that hasn’t been confirmed for a while, which is that people can make a vaccine for COVID-19 that will provide strong immunity from the disease. The closer humanity to the vaccine, the more appropriate it does to not spread the virus.
It means that every person who will not fall sick to the virus in the next months to come is someone who might never get sick from this disease. The whole world has been suffering from this pandemic for not less than eight months already and is continually in misery because of the major setbacks caused by this global health crisis. Everyone has their hopes up for a vaccine that could end this grave situation that we have, and we can finally go back to our old normal.
However, there are still hesitations because of the safety issues of the announced vaccines from major pharmaceutical companies. Safety and quality indeed should be the top priority because here lies the life of humanity. Pfizer and Biotech are working on this and holds a great promise on ending this global pandemic, saving millions of lives in the process.
Why Is It So Hard to Like Healthy Food?
Let's get to it! Why does it seem so hard for people to eat healthy?
Things to Keep in Mind Before Starting a Keto Diet
The keto diet is a trending eating plan these days. For those who are aiming to shed some pounds and get their figure back, this diet is considered by several dieting proponents to be more convenient than dieting that involves fasting or starving.
How Covid-19 Has Drastically Changed the Tourism Industry and How People Travel
Tourism is among the fundamental contributors to the GDP of any economy. For this and many other reasons, the effect of Covid-19 on the tourism sector is one we cannot downplay.
Senior Care: Important Things That You Should Know To Make Them Happy
One of the key distinctions between humans and irrational animals is that we have, or at least should have, a very clear need and way of taking care of our elderly.
10 Proven Techniques To Stay Focused On Your Dreams
Focusing on your desires is vital for successful manifestation! After all, energy flows where your attention goes…How can you channel more of that?
6 Critical Manifestation Mistakes That Can Backfire On You
Just a heads up, This Post May Contain Affiliate Links, Read My Disclaimer For More Information!Are these mistakes backfiring on your ability to manifest? In today’s article you will learn what these common faults are & how to eliminate them so you can become a powerful magnet to attract any goal or desire you wish ... Read more6 Critical Manifestation Mistakes That Can Backfire On You
Deep Sleep in Two Minutes
Frequency to listen for a better sleep and benefits it can give to the listener
Food for the Bones
Strong bones are a sign of good health. A balanced diet can help to produce the required level of calcium! Let's readout how to make a balanced diet!
Hair Growth Treatment Choices for Your Thinning Mane
The most important prerequisite of choosing a hair regrowth treatment option is to determine the cause of one’s hair loss problem. Hair loss may be caused by several reasons
Top 17 Online Spiritual Healing Courses in 2021
Here are the latest courses available in 2021 for those aspiring to become spiritual healers.
Landscape’s Backbones: 11 Herbaceous Plants You Can Grow In Your Garden
Herbaceous plants are highly considered the backbone of any garden. They can brighten up any garden, no matter how simple they look.